Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
Recruiting
N/A
Interventional Study
Myofascial Pain Dysfunction Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 28 (estimated)
- Sponsor
- Cairo University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patient…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age between 18 and 70 years.
2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
4. Pain duration ≥ 3 months.
5. Pain intensity ≥ 4 on the Vi…
Contacts
Khaled A Elhayes, PhD
+20 1030000360
CONTACT